Jun 27, 2023

Featuring perspectives from Dr Philipp Harter, Dr David M O’Malley and Dr Shannon N Westin, including the following topics:

• Up-Front Treatment for Advanced Ovarian Cancer (OC)
  • Introduction (0:00)
  • Front-line maintenance therapy for patients with advanced OC (3:11)
  • Adverse events associated with PARP inhibitors and implications for therapeutic selection (14:17)
  • Other considerations for patients with advanced ovarian cancer and germline BRCA mutations: Management of the breast, role of genetic counseling, et cetera  (31:03)
• The Evolving Management Paradigm for Relapsed/Refractory OC
  • PARP inhibitors as later-line therapy for advanced OC (35:20)
  • Use of mirvetuximab soravtansine in advanced OC  (44:04)
• Novel Agents and Strategies Under Investigation for Advanced OC
  • Upifitamab rilsodotin in advanced OC (50:10)
  • Tumor treating fields in advanced OC (56:03)

CME information and select publications